721 results about "Pharmacologic therapy" patented technology

A patient is diagnosed and a regimen of treatment is prescribed in a system which tests the patients, receives test results from a patient, including DNA test results. A database of human genome data correlating human health disorder with DNA genetic tests is accessed. A database of environmental factors which correlate known human health disorders with environmental conditions is accessed. Risk factors including genetic risk and environmental risk are developed, and from these, a composite risk factor is developed. This is used to access a database of prescribed drug therapy.

Methods and compositions for medical imaging, evaluating intracellular processes and components, radiotherapy of intracellular targets, and drug delivery by the use of novel cell membrane-permeant peptide conjugate coordination and covalent complexes having target cell specificity are provided. Kits for conjugating radionuclides and other metals to peptide coordination complexes are also provided.

A system is provided that integrates of records of clinical laboratory services into the assessment and optimization of patient health care and, in particular, regulation of the use of pharmaceuticals. Laboratory test result records are used in conjunction with other health care benefits records to monitor regulation of use of pharmaceuticals by patients. The incorporation of laboratory tests and results into such a utilization system allows improvement in the management of a patient's therapy based on a more precise picture of the patient's level of illness as revealed by the laboratory test results. The system of the present invention also allows optimization of the selection of laboratory tests to be performed, and also provides an outcome assessment of the risk of hospitalization due to pharmaceutical treatments resulting in physician intervention, leading to a change in physician prescribing behavior and, accordingly, a decrease in drug induced hospitalizations and improved quality of patient care and savings of health care costs.

The invention provides an androgen receptor antagonist for resisting the prostate cancer, relates to a sulfoimidazoledione with substituted groups on two nitrogen atoms, and relates to a use of such the compounds as a medicament for treating the diseases or disorders related to the androgen receptor, such as prostate cancer, alopecia or whelk.

The invention discloses bifidobacterium longum and the application thereof and belongs to the technical field of biologics. The invention provides a bifidobacterium longum YS108R strain which has thecharacteristic of generating viscous exopolysaccharide, and has a remarkable improvement function on DSS (Dextran Sulfate Sodium) induced mouse colitis models. The strain has a relatively good capability of enduring simulated gastrointestinal fluids, is capable of remarkably reducing disease activity indexes of mice in the DSS induction period, and has an effective protection function on colon tissue. In addition, the bifidobacterium longum YS108R disclosed by the invention is separated from intestinal florae of healthy people, is free of toxic and/or side effects on human bodies, and has certain advantages when being compared with conventional medicine treatment. The strain can be used for preparing probiotic powder, fermented milk, and the like, and has wide market prospects.

The invention provides novel compositions, methods and uses, for the diagnosis, prognosis, prediction, prevention and aid in treatment of malignant neoplasia such as breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer. Genes that are chromosomally amplified in breast tissue of breast cancer patients are disclosed. Further disclosed are chromosomally amplified genes and non-amplified genes that correlate to Taxane resistance, Taxane benefit or adverse Taxane reaction, which can be used as an aid to make therapy dicisions.

Methods and systems are disclosed that characterize cardiac function using an acceleration sensor to acquire and analyze the frequency dynamics associated with the isovolumic contraction phase (“ICP”). This information can be used to characterize heart function; optimize therapy for cardiomyopathy, including CRT therapy (including pacing intervals and required pharmacologic therapy); and to optimize CCM therapy. In addition, this information can be used to identify target pacing regions for CRT lead placement. Further, analyzing the frequency dynamics can be used to characterize pathologic heart vibrational motion, such as mitral regurgitation and the third or fourth heart sound, and the response of this motion to therapy for cardiomyopathy.

The present invention concerns a method for predicting the relative efficacy of a plurality of drugs for treating a tumour in an individual comprising the molecular characterization of the tumour, and the calculation of a score for the plurality of drug essentially based on the percentage of deregulated target gene.

The present invention provides an antihuman TNF-α antibody activity lowering inhibitor comprising a protein source(s) and/or carbohydrate source(s), in the treatment of inflammatory bowel syndrome with repeated administration of anti-TNF-α antibody; and a kit preparation wherein a freeze-dried antihuman TNF-α antibody and the activity lowering inhibitor in the above repeated administration of the anti-TNF-α antibody are separately contained in a plastic container so that they can communicate with each other. According to the present invention, in the drug therapy to the patients with inflammatory bowel syndrome, therapeutic agents which inhibit the inflammation for long periods without accompanying serious side effects can be provided.

The invention relates to a new pharmacotherapeutical strategy, to an anti-stress, anti-impairment and anti-aging drug and to a process for its manufacturing. The drug has an etio-pathogenic and homeostatic action, was preclinically tested and clinically checked up in geriatric, neurologic, psychiatric and stress-dependent pathology. The drug achieves a synergistic biological, neurometabolic and cell-trophic composition, being elaborated by the association of the following active principles: a) against oxidative and catabolic stress; methionine with aminoethanol phenoxyacetates and/or aminoethyl phenoxyacetamides; b) against anabolic stress; hydroxopyrimidine carboxylates and/or oxopyrrolidine acetamides with potassium, zinc and lithium; c) vasodilative and normolipidemic; nicotinic, alcohol and/or acid, or its derivatives, with magnesium and iodine; d) energo-active and e) anti-toxic; aspartate; fructose; vitamin B1; vitamin B6; monoacid phosphate and sulfate. The process for manufacturing the drug stipulates; a) pharmaceutical preparation in two complementary types of capsules or coated tablets, gastrosoluble and enterosoluble, the last being enteric coated; b) prolonged-release of vasodilator from the enterosoluble unit.

The invention relates to a cell phone based physical and psychological adjustment device through physical factors of music and color shade, which integrates a physical treatment effect of the physical and physiological treatment on the basis of a physical therapy, a psychological treatment effect of psychological treatment on the basis of a music therapy, and a permanent cure effect of the traditional Chinese meridian and acupuncture point therapy, and is also added with the chromophototherapy so as to achieve the purpose of treating the body, the mind and the radical causes at the same time and embody a new biological-psychological-social medical mode, which is a brand-new non pharmacological treating mode. A positioning technology and an Internet technology are integrated into the adjustment device, which is convenient for establishing a medical care network system; a biological information sensor is applied so that the adjustment device can detect a treating effect instantly, and is also used for building a moving environment of a user of the adjustment device into a scientific environment; various physical factors are blended into the same physical therapy functional module; and one or a plurality of physical factors can be selected for simultaneous treatment so as to ensure a treating effect. By using biological information detection and the Internet technology of the adjustment device, remote monitoring can be realized.

The invention discloses a traditional Chinese medicine composition for treating gastric cancer, and relates to the technical field of traditional Chinese medicines, to solve the problem that no effective medicine is available for treating the gastric cancer. The traditional Chinese medicine composition is the traditional Chinese medicine preparation comprising burdock, fig, gallnut, gallnut, daemonorops draco, manis pentadactyla, astragalus mongholicus, angelica sinensis and liquorice. The traditional Chinese medicine composition disclosed by the invention has high anti-cancer activity for solid tumor such as gastric cancer, and has few side effects, is capable of improving the immunocompetence of a patient, and is suitable for the clinical patient with the gastric cancer.

A method of administering an over the counter drug for treatment of a chronic medical condition to a patient is provided wherein a drug label for over-the-counter treatment of a chronic medical condition is created which requires a new patient to take an initial point-of-service diagnostic test to determine whether the patient suffers from the condition treated by the drug and requires patients already receiving the drug on an over-the-counter basis to take one or more follow up point-of-service diagnostic tests to determine whether the patient is benefiting from the drug and are not experiencing undue side effects. Patients determined eligible to take the drug may then be provided with a random access code for use in association with a lockable, electromechanical cabinet by means of which the patient can receive an appropriate dose of the drug to treat the patient's chronic medical condition. In certain embodiments, a follow up point-of-service diagnostic test determines whether the patient is experiencing any undue side effects from the drug. In further embodiments, a national patient registry for containing the point of service diagnostic test results is created for access by appropriate health care professionals.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

The invention relates to compositions and methods for a one-step synthetic technique for making cationic steroid pharmaceutical compositions for use in treating inflammation and other diseases and disorders.

A biomarker that correlates to treatment with drugs that inhibit FMS is disclosed. This biomarker has been shown to have utility in assessing response to the compounds. The plasma level of the biomarker is increased upon treatment with FMS inhibitor compounds, thus indicating that this biomarker is involved in FMS activity.